MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer

Michael J.G. Milevskiy, Udai Gujral, Carolina Del Lama Marques, Andrew Stone, Korinne Northwood, Lez J. Burke, Julia M.W. Gee, Kenneth Nephew, Susan Clark, Melissa A. Brown

Research output: Contribution to journalArticle

Abstract

Background: MicroRNAs are potent post-transcriptional regulators involved in all hallmarks of cancer. Mir-196a is transcribed from two loci and has been implicated in a wide range of developmental and pathogenic processes, with targets including Hox, Fox, Cdk inhibitors and annexins. Genetic variants and altered expression of MIR196A are associated with risk and progression of multiple cancers including breast cancer, however little is known about the regulation of the genes encoding this miRNA, nor the impact of variants therein. Methods: Genomic data and chromatin interaction analysis were used to discover functional promoter and enhancer elements for MIR196A. Expression data were used to associate MIR196A with mechanisms of resistance, breast cancer subtypes and prognosis. Results: Here we demonstrate that MIR196A displays complex and dynamic expression patterns, in part controlled by long-range transcriptional regulation between promoter and enhancer elements bound by ERα. Expression of this miRNA is significantly increased in drug-resistant models of hormone-receptor positive disease. The expression of MIR196A also proves to be a robust prognostic factor for patients with advanced and post-menopausal ER+ disease. Conclusion: This work sheds light on the normal and abnormal regulation of MIR196A and provides a novel stratification method for therapeutically resistant breast cancer.

Original languageEnglish (US)
JournalBritish Journal of Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

MicroRNAs
Biomarkers
Breast Neoplasms
Annexins
Chromatin
Hormones
Pharmaceutical Preparations
Genes
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Milevskiy, M. J. G., Gujral, U., Del Lama Marques, C., Stone, A., Northwood, K., Burke, L. J., ... Brown, M. A. (2019). MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-019-0395-8

MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer. / Milevskiy, Michael J.G.; Gujral, Udai; Del Lama Marques, Carolina; Stone, Andrew; Northwood, Korinne; Burke, Lez J.; Gee, Julia M.W.; Nephew, Kenneth; Clark, Susan; Brown, Melissa A.

In: British Journal of Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Milevskiy, MJG, Gujral, U, Del Lama Marques, C, Stone, A, Northwood, K, Burke, LJ, Gee, JMW, Nephew, K, Clark, S & Brown, MA 2019, 'MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer', British Journal of Cancer. https://doi.org/10.1038/s41416-019-0395-8
Milevskiy, Michael J.G. ; Gujral, Udai ; Del Lama Marques, Carolina ; Stone, Andrew ; Northwood, Korinne ; Burke, Lez J. ; Gee, Julia M.W. ; Nephew, Kenneth ; Clark, Susan ; Brown, Melissa A. / MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer. In: British Journal of Cancer. 2019.
@article{1a0b09a3c52f4f4c8df2cfd2e513977c,
title = "MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer",
abstract = "Background: MicroRNAs are potent post-transcriptional regulators involved in all hallmarks of cancer. Mir-196a is transcribed from two loci and has been implicated in a wide range of developmental and pathogenic processes, with targets including Hox, Fox, Cdk inhibitors and annexins. Genetic variants and altered expression of MIR196A are associated with risk and progression of multiple cancers including breast cancer, however little is known about the regulation of the genes encoding this miRNA, nor the impact of variants therein. Methods: Genomic data and chromatin interaction analysis were used to discover functional promoter and enhancer elements for MIR196A. Expression data were used to associate MIR196A with mechanisms of resistance, breast cancer subtypes and prognosis. Results: Here we demonstrate that MIR196A displays complex and dynamic expression patterns, in part controlled by long-range transcriptional regulation between promoter and enhancer elements bound by ERα. Expression of this miRNA is significantly increased in drug-resistant models of hormone-receptor positive disease. The expression of MIR196A also proves to be a robust prognostic factor for patients with advanced and post-menopausal ER+ disease. Conclusion: This work sheds light on the normal and abnormal regulation of MIR196A and provides a novel stratification method for therapeutically resistant breast cancer.",
author = "Milevskiy, {Michael J.G.} and Udai Gujral and {Del Lama Marques}, Carolina and Andrew Stone and Korinne Northwood and Burke, {Lez J.} and Gee, {Julia M.W.} and Kenneth Nephew and Susan Clark and Brown, {Melissa A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41416-019-0395-8",
language = "English (US)",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer

AU - Milevskiy, Michael J.G.

AU - Gujral, Udai

AU - Del Lama Marques, Carolina

AU - Stone, Andrew

AU - Northwood, Korinne

AU - Burke, Lez J.

AU - Gee, Julia M.W.

AU - Nephew, Kenneth

AU - Clark, Susan

AU - Brown, Melissa A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: MicroRNAs are potent post-transcriptional regulators involved in all hallmarks of cancer. Mir-196a is transcribed from two loci and has been implicated in a wide range of developmental and pathogenic processes, with targets including Hox, Fox, Cdk inhibitors and annexins. Genetic variants and altered expression of MIR196A are associated with risk and progression of multiple cancers including breast cancer, however little is known about the regulation of the genes encoding this miRNA, nor the impact of variants therein. Methods: Genomic data and chromatin interaction analysis were used to discover functional promoter and enhancer elements for MIR196A. Expression data were used to associate MIR196A with mechanisms of resistance, breast cancer subtypes and prognosis. Results: Here we demonstrate that MIR196A displays complex and dynamic expression patterns, in part controlled by long-range transcriptional regulation between promoter and enhancer elements bound by ERα. Expression of this miRNA is significantly increased in drug-resistant models of hormone-receptor positive disease. The expression of MIR196A also proves to be a robust prognostic factor for patients with advanced and post-menopausal ER+ disease. Conclusion: This work sheds light on the normal and abnormal regulation of MIR196A and provides a novel stratification method for therapeutically resistant breast cancer.

AB - Background: MicroRNAs are potent post-transcriptional regulators involved in all hallmarks of cancer. Mir-196a is transcribed from two loci and has been implicated in a wide range of developmental and pathogenic processes, with targets including Hox, Fox, Cdk inhibitors and annexins. Genetic variants and altered expression of MIR196A are associated with risk and progression of multiple cancers including breast cancer, however little is known about the regulation of the genes encoding this miRNA, nor the impact of variants therein. Methods: Genomic data and chromatin interaction analysis were used to discover functional promoter and enhancer elements for MIR196A. Expression data were used to associate MIR196A with mechanisms of resistance, breast cancer subtypes and prognosis. Results: Here we demonstrate that MIR196A displays complex and dynamic expression patterns, in part controlled by long-range transcriptional regulation between promoter and enhancer elements bound by ERα. Expression of this miRNA is significantly increased in drug-resistant models of hormone-receptor positive disease. The expression of MIR196A also proves to be a robust prognostic factor for patients with advanced and post-menopausal ER+ disease. Conclusion: This work sheds light on the normal and abnormal regulation of MIR196A and provides a novel stratification method for therapeutically resistant breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85061912144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061912144&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0395-8

DO - 10.1038/s41416-019-0395-8

M3 - Article

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -